Christi J Van Asperen

List of Publications by Year
in descending order

155	11,898	34105	30922
papers	citations	52 h-index	102 g-index

159	159	159	15564
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas. Clinical Gastroenterology and Hepatology, 2022, 20, e496-e507.	4.4	14
2	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
3	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	2.4	10
4	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast, 2022, 61, 98-107.	2.2	6
5	Recommendations for reporting results of diagnostic genomic testing. European Journal of Human Genetics, 2022, 30, 1011-1016.	2.8	15
6	Genetic clinicians' confidence in <scp>BOADICEA</scp> comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study. Clinical Genetics, 2022, 102, 30-39.	2.0	3
7	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
8	Association between a 46-SNP Polygenic Risk Score and melanoma risk in Dutch patients with familial melanoma. Journal of Medical Genetics, 2021, 58, 760-766.	3.2	8
9	Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making. Journal of Community Genetics, 2021, 12, 101-110.	1.2	6
10	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Research Protocols, 2021, 10, e24414.	1.0	9
11	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
12	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
13	Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. Journal of the National Cancer Institute, 2021, 113, 1203-1211.	6.3	44
14	The predictive ability of the 313 variantâ€"based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
15	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. Npj Breast Cancer, 2021, 7, 98.	5.2	4
16	Response to Nahshon and Lavie. Journal of the National Cancer Institute, 2021, , .	6.3	0
17	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
18	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120

#	Article	IF	Citations
19	Clustering of known low and moderate risk alleles rather than a novel recessive highâ€risk gene in nonâ€BRCA1 /2 sib trios affected with breast cancer. International Journal of Cancer, 2020, 147, 2708-2716.	5.1	2
20	Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2. Genetics in Medicine, 2020, 22, 1355-1365.	2.4	23
21	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
22	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
23	Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats . Patient Preference and Adherence, 2020, Volume 14, 333-342.	1.8	4
24	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
25	Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations. , 2020, , .		0
26	The functional impact of variants of uncertain significance in BRCA2. Genetics in Medicine, 2019, 21, 293-302.	2.4	58
27	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 177, 723-733.	2.5	111
28	Breast Cancer Susceptibilityâ€"Towards Individualised Risk Prediction. Current Genetic Medicine Reports, 2019, 7, 124-135.	1.9	4
29	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
30	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
31	An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genetics in Medicine, 2019, 21, 2706-2712.	2.4	11
32	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
33	Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2breast cancer families. Journal of Medical Genetics, 2019, 56, 581-589.	3.2	35
34	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
35	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
36	Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clinical Cancer Research, 2019, 25, 7517-7526.	7.0	34

#	Article	IF	Citations
37	Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch nonâ€CDKN2A/CDK4 melanoma families. International Journal of Cancer, 2019, 144, 2453-2464.	5.1	33
38	Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decisionâ€making. Journal of Genetic Counseling, 2019, 28, 533-542.	1.6	14
39	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
40	A functional assayâ€"based procedure to classify mismatch repair gene variants in Lynch syndrome. Genetics in Medicine, 2019, 21, 1486-1496.	2.4	36
41	The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study. Familial Cancer, 2019, 18, 137-146.	1.9	17
42	The BRCA2 c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	2.5	19
43	CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe. Journal of Medical Genetics, 2018, 55, 661-668.	3.2	13
44	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
45	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	6.4	12
46	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Scientific Reports, 2018, 8, 6574.	3.3	51
47	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	2.9	33
48	Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. British Journal of Cancer, 2018, 119, 357-363.	6.4	22
49	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. Journal of Molecular Diagnostics, 2018, 20, 600-611.	2.8	18
50	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Modern Pathology, 2017, 30, 509-518.	5.5	32
51	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
52	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. European Journal of Cancer, 2017, 82, 219-227.	2.8	71
53	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	2.2	76
54	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099

#	Article	IF	Citations
55	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
56	Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists. PLoS ONE, 2017, 12, e0178447.	2.5	9
57	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
58	Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility GeneXRCC2. Human Mutation, 2016, 37, 914-925.	2.5	12
59	Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. European Journal of Cancer, 2016, 61, 137-145.	2.8	64
60	Comprehensive Mutation Analysis ofPMS2in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome. Human Mutation, 2016, 37, 1162-1179.	2.5	50
61	Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. European Journal of Cancer, 2016, 69, 127-134.	2.8	49
62	Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?. Menopause, 2016, 23, 903-910.	2.0	22
63	Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1251-1258.	2.5	9
64	Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes. Human Mutation, 2016, 37, 331-336.	2.5	31
65	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Human Molecular Genetics, 2016, 25, 2256-2268.	2.9	106
66	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
67	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
68	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
69	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
70	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
71	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e19-202.e28.	1.6	8
72	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	2.9	91

#	Article	IF	Citations
73	General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles. BMC Cancer, 2015, 15, 243.	2.6	6
74	Next-Generation Diagnostics: Gene Panel, Exome, or Whole Genome?. Human Mutation, 2015, 36, 648-655.	2.5	124
75	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
76	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
77	Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program. , 2015, , .		20
78	Breast surgeons' attitudes towards bilateral risk-reducing mastectomy: A National Survey of American Surgeons.. Journal of Clinical Oncology, 2015, 33, 25-25.	1.6	3
79	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
80	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
81	Meaningâ€centered group psychotherapy in cancer survivors: a feasibility study. Psycho-Oncology, 2014, 23, 827-831.	2.3	19
82	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
83	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics, 2014, 51, 98-107.	3.2	74
84	Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2482-2491.	2.5	11
85	Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities. Journal of Community Genetics, 2014, 5, 69-79.	1.2	16
86	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	1.9	195
87	Relevance and efficacy of breast cancer screening inBRCA1andBRCA2mutation carriers above 60 years: A national cohort study. International Journal of Cancer, 2014, 135, 2940-2949.	5.1	13
88	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
89	Effectiveness and cost-effectiveness of meaning-centered group psychotherapy in cancer survivors: protocol of a randomized controlled trial. BMC Psychiatry, 2014, 14, 22.	2.6	44
90	CHEK2*1100delC homozygosity in the Netherlandsâ€"prevalence and risk of breast and lung cancer. European Journal of Human Genetics, 2014, 22, 46-51.	2.8	29

#	Article	IF	Citations
91	The counselees' selfâ€reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters. Psycho-Oncology, 2013, 22, 902-910.	2.3	35
92	Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment. Psycho-Oncology, 2013, 22, 1167-1176.	2.3	19
93	The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial. BMC Medical Informatics and Decision Making, 2013, 13, 55.	3.0	10
94	Value-based healthcare in Lynch syndrome. Familial Cancer, 2013, 12, 347-354.	1.9	6
95	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
96	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
97	Variants of Uncertain Significance inBRCA1andBRCA2assessment of in silico analysis and a proposal for communication in genetic counselling. Journal of Medical Genetics, 2013, 50, 74-79.	3.2	21
98	Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles. PLoS ONE, 2013, 8, e55681.	2.5	95
99	Efficacy of risk-reducing mastectomy (RRM) on overall survival (OS) in BRCA1/2-associated breast cancer (BC) patients.. Journal of Clinical Oncology, 2013, 31, 1502-1502.	1.6	3
100	Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling. PLoS ONE, 2013, 8, e55734.	2.5	29
101	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
102	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. Journal of Medical Genetics, 2012, 49, 525-532.	3.2	97
103	Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, The, 2012, 345, e5660-e5660.	6.0	186
104	Rare variants in XRCC2 as breast cancer susceptibility alleles: TableÂ1. Journal of Medical Genetics, 2012, 49, 618-620.	3.2	49
105	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	2.5	11
106	Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2â€result. Psycho-Oncology, 2012, 21, 29-42.	2.3	60
107	Urologistsâ€™ and GPsâ€™ knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands. Familial Cancer, 2012, 11, 195-200.	1.9	6
108	MUTYH gene variants and breast cancer in a Dutch caseâ€“control study. Breast Cancer Research and Treatment, 2012, 134, 219-227.	2.5	38

#	Article	IF	Citations
109	Exploring the short-term impact of DNA-testing in breast cancer patients: The counseleesâ€™ perception matters, but the actual BRCA1/2 result does not. Patient Education and Counseling, 2012, 86, 239-251.	2.2	31
110	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
111	A counselee-oriented perspective on risk communication in genetic counseling: Explaining the inaccuracy of the counselees' risk perception shortly after BRCA1/2 test result disclosure. Genetics in Medicine, 2011, 13, 800-811.	2.4	25
112	Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Breast Cancer Research, 2011, 13, R72.	5.0	35
113	The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell, 2011, 19, 273-282.	16.8	104
114	A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Familial Cancer, 2011, 10, 87-96.	1.9	48
115	Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2011, 126, 193-202.	2.5	59
116	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	3.8	18
117	Genetic testing for familial/hereditary breast cancerâ€”comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. Journal of Community Genetics, 2011, 2, 53-69.	1.2	59
118	Family communication matters: The impact of telling relatives about unclassified variants and uninformative DNA-test results. Genetics in Medicine, 2011, 13, 333-341.	2.4	33
119	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
120	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
121	Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 120, 235-244.	2.5	79
122	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
123	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	5.0	25
124	TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. Journal of Medical Genetics, 2010, 47, 421-428.	3.2	254
125	Disentangling the Babylonian speech confusion in genetic counseling: An analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic. Genetics in Medicine, 2009, 11, 742-749.	2.4	6
126	A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer, 2009, 9, 211.	2.6	57

#	Article	IF	Citations
127	Intronic variants inBRCA1andBRCA2that affect RNA splicing can be reliably selected by splice-site prediction programs. Human Mutation, 2009, 30, 107-114.	2.5	97
128	Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?. Breast Cancer Research and Treatment, 2009, 115, 381-390.	2.5	88
129	A 7 Mb region within 11q13 may contain a high penetrance gene for breast cancer. Breast Cancer Research and Treatment, 2009, 118, 151-159.	2.5	23
130	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	21.4	434
131	A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2genes based on cancer family history. Breast Cancer Research, 2009, 11, R8.	5.0	45
132	The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psycho-Oncology, 2008, 17, 822-830.	2.3	112
133	Genomeâ€wide linkage scan in Dutch hereditary nonâ€BRCA1/2 breast cancer families identifies 9q21â€22 as a putative breast cancer susceptibility locus. Genes Chromosomes and Cancer, 2008, 47, 947-956.	2.8	16
134	A family history of breast cancer will not predict female early onset breast cancer in a population-based setting. BMC Cancer, 2008, 8, 203.	2.6	9
135	Design of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counselling. BMC Cancer, 2008, 8, 283.	2.6	17
136	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. PLoS Genetics, 2008, 4, e1000054.	3.5	315
137	Putting it all behind: long-term psychological impact of an inconclusive DNA test result for breast cancer. Genetics in Medicine, 2008, 10, 745-750.	2.4	16
138	Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. Genetics in Medicine, 2007, 9, 173-179.	2.4	17
139	Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing. European Journal of Cancer, 2007, 43, 71-77.	2.8	36
140	Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Research, 2007, 9, R78.	5.0	64
141	Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. Patient Education and Counseling, 2007, 65, 58-68.	2.2	55
142	A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. Psycho-Oncology, 2007, 16, 320-328.	2.3	52
143	The common sense model of selfâ€regulation and psychological adjustment to predictive genetic testing: a prospective study. Psycho-Oncology, 2007, 16, 1121-1129.	2.3	44
144	Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. BMC Genomics, 2007, 8, 299.	2.8	26

#	Article	IF	Citations
145	A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 2006, 45, 646-655.	2.8	111
146	Clinical Characteristics Affect the Impact of an Uninformative DNA Test Result: The Course of Worry and Distress Experienced by Women Who Apply for Genetic Testing for Breast Cancer. Journal of Clinical Oncology, 2006, 24, 3672-3677.	1.6	84
147	Whatâ€™s the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genetics in Medicine, 2005, 7, 239-245.	2.4	55
148	Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. European Journal of Human Genetics, 2005, 13, 525-527.	2.8	25
149	Homozygosity for aCHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. Journal of Pathology, 2005, 206, 198-204.	4.5	24
150	Risk Estimation for Healthy Women from Breast Cancer Families: New Insights and New Strategies. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 87-93.	2.5	41
151	A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. Laboratory Investigation, 2004, 84, 191-202.	3.7	11
152	Feeling at risk: How women interpret their familial breast cancer risk. American Journal of Medical Genetics Part A, 2004, 131A, 42-49.	2.4	25
153	Variants of Uncertain Clinical Significance as a Result of BRCA1/2 Testing: Impact of an Ambiguous Breast Cancer Risk Message. Genetic Testing and Molecular Biomarkers, 2004, 8, 235-239.	1.7	42
154	How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study. BMJ: British Medical Journal, 2001, 322, 26-27.	2.3	16
155	Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype-phenotype correlations in neurofibromatosis type 1?. Human Mutation, 1997, 9, 458-464.	2.5	109